Sign in Subscribe
Nanotechnology

Dual-Responsive Magnetic and pH-Sensitive Beads for Glioblastoma Treatment

Strategic Insights

— 1 min read

A new research study aimed to develop and evaluate dual-responsive magnetic and pH-sensitive beads for controlled cisplatin delivery to glioblastoma cell lines. The study, conducted by researchers at Kerman University of Medical Sciences in Iran, involved synthesizing cobalt ferrite nanoparticles using a green co-precipitation method and incorporating them into sodium alginate beads with cisplatin. The beads exhibited pH-dependent swelling and significantly enhanced drug release under a magnetic field, achieving 70.2% cisplatin release in 80 minutes. The study concluded that these dual-responsive beads offer a promising platform for targeted cisplatin delivery in glioblastoma, potentially improving therapeutic outcomes while minimizing systemic toxicity.

Key Takeaways:

  • Researchers at Kerman University of Medical Sciences developed dual-responsive magnetic and pH-sensitive beads for controlled cisplatin delivery to glioblastoma cell lines.
  • The beads were synthesized using a green co-precipitation method involving cobalt ferrite nanoparticles and sodium alginate.
  • The beads exhibited pH-dependent swelling, with maximum absorption at pH 7.4.
  • Drug release was significantly enhanced under a 100 Hz magnetic field, achieving 70.2% cisplatin release in 80 minutes for CisB-4 beads.
  • The beads demonstrated significant cytotoxicity against T98 and A172 cells, with p < 0.001.
  • These dual-responsive beads offer a promising platform for targeted cisplatin delivery in glioblastoma, potentially improving therapeutic outcomes while minimizing systemic toxicity.

Statistics:

  • 70.2% cisplatin release in 80 minutes under a 100 Hz magnetic field for CisB-4 beads.
  • p < 0.001 for cytotoxicity against T98 and A172 cells.
  • The study concluded that these dual-responsive beads might improve therapeutic outcomes in glioblastoma patients.
  • The beads had maximum absorption at pH 7.4.

Sources:

  • Medical Oncology, 2025;42(7):247. Medical Oncology can be contacted at: Humana Press Inc, 999 Riverview Drive Suite 208, Totowa, NJ 07512, USA.
  • Nanotechnology Weekly. June 23, 2025; p 1409.

Read more